These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10582540)

  • 21. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women.
    Larrea F; Escorza A; Valencia X; Méndez I; Schiavon R; Forsbach G
    Rev Invest Clin; 1991; 43(4):293-8. PubMed ID: 1798861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
    Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
    J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects.
    Anderson PW; Malarkey WB; Salk J; Kletsky OA; Hsueh WA
    J Clin Endocrinol Metab; 1989 Sep; 69(3):518-22. PubMed ID: 2503532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
    Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
    J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia.
    Sluijmer AV; Lappöhn RE
    Fertil Steril; 1992 Jul; 58(1):72-7. PubMed ID: 1624026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome.
    Valensi P; Combes ME; Perret G; Attali JR
    J Endocrinol Invest; 1996 May; 19(5):293-7. PubMed ID: 8796337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of verapamil on diurnal and thyrotropin-releasing hormone-stimulated prolactin levels in man.
    Nielsen-Kudsk JE; Bartels PD; Dalby J
    J Clin Endocrinol Metab; 1990 May; 70(5):1269-72. PubMed ID: 2110572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
    Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
    Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The reaction of the hypophysis to thyroliberin and metoclopramide in women with hyperprolactinemia].
    Tkachenko NN; Potin VV; Beskrovnyĭ SV; Nosova LG
    Probl Endokrinol (Mosk); 1990; 36(2):35-40. PubMed ID: 2114023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
    Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
    Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prolactin variants in serum and amniotic fluid of women with ovulatory hyperprolactinemia].
    Larrea F; Escorza A; Méndez I; Ruiz JE; Valero A; Cravioto MC
    Rev Invest Clin; 1991; 43(3):245-51. PubMed ID: 1818370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
    Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
    Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does elevated morning prolactin concentration in children always mean the diagnosis of hyperprolactinemia?
    Stawerska R; Smyczyńska J; Hilczer M; Lewiński A
    Exp Clin Endocrinol Diabetes; 2015 Jul; 123(7):405-10. PubMed ID: 26069077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man.
    Veldhuis JD; Borges JL; Drake CR; Rogol AD; Kaiser DL; Thorner MO
    J Clin Endocrinol Metab; 1985 Jan; 60(1):144-9. PubMed ID: 3880562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.
    Nicoletti I; Filipponi P; Sfrappini M; Fedeli L; Petrelli S; Gregorini G; Santeusanio F; Brunetti P
    Horm Res; 1984; 19(3):158-70. PubMed ID: 6425187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing's disease.
    Gheri RG; Boddi W; Ammannati F; Olivotto J; Nozzoli C; Franchi A; Bordi L; Luisi ML; Mennonna P
    J Endocrinol Invest; 1997 Apr; 20(4):240-4. PubMed ID: 9211134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Importance of prolactin isoforms on ovary function in hyperprolactinemic women].
    Romero C; León J; Jara R; González O
    Rev Chil Obstet Ginecol; 1993; 58(6):465-9. PubMed ID: 7991872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
    Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
    Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia.
    Dallabonzana D; Spelta B; Botalla L; Oppizzi G; Silvestrini F; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1125-8. PubMed ID: 7076795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.